Clinical regressions and broad immune activation following combination therapy targeting human NKT cells

in myeloma

by Joshua Richter, Natalia Neparidze, Lin Zhang, Shiny Nair, Tamara Monesmith, Ranjini Sundaram, Fred Miesowicz, Kavita M. Dhodapkar, and Madhav V.

Dhodapkar

BloodVolume 121(3):423-430

January 17, 2013

©2013 by American Society of Hematology

Study schema.

Joshua Richter et al. Blood 2013;121:423-430

©2013 by American Society of Hematology

Changes in NKT cells.

Joshua Richter et al. Blood 2013;121:423-430

©2013 by American Society of Hematology

Changes in NK cells.

Joshua Richter et al. Blood 2013;121:423-430

©2013 by American Society of Hematology

Changes in other innate cells and cytokines.

Joshua Richter et al. Blood 2013;121:423-430

©2013 by American Society of Hematology

Clinical effects of therapy.

Joshua Richter et al. Blood 2013;121:423-430

©2013 by American Society of Hematology

Changes in T-cell immunity.

Joshua Richter et al. Blood 2013;121:423-430

©2013 by American Society of Hematology